Sumanta Kumar Pal, Professor of Medical Oncology and Therapeutics Research, Co-director of the Kidney Cancer Program at City of Hope National Medical Center, shared a post on X:
“Terrific discussion: the greatest challenges and opportunities for precision medicine in various tumor types with Chris Chen and Tim Ellis Caleo from Stanford Cancer Institute, Aditya Shreenivas from City of Hope and my long-time friend and former MOASC President Ashkan Lashkari.
Some heated discussion around the IPREDICT study with Razelle Kurzrock and optimal platforms for genomic testing.
Great start to the MOASC and ANCO Precision Oncology Symposium!”
ANCO and MOASC Precision Oncology Symposium 2026
- Focus on precision oncology: Organized by the Association of Northern California Oncologists (ANCO) and the Medical Oncology Association of Southern California (MOASC), the symposium focuses on translating molecular tumor profiling and advances in targeted therapies into personalized cancer care.
- Multidisciplinary scientific program: The event addresses precision medicine across gastrointestinal, genitourinary, lung, breast, and gynecologic cancers, highlighting emerging therapeutic opportunities and clinical applications.
- Key educational objectives: Sessions explore the integration of germline and somatic genomic findings, tumor-agnostic FDA approvals, biomarker-driven treatment decisions, and challenges associated with genomic testing.
- Patient-centered care and continuing education: The symposium emphasizes collaboration with patient advocates to improve access to biomarker-driven care and offers up to 5.75 AMA PRA Category 1 Credits™ for participating healthcare professionals.
You may also be interested in:
The ANCO and MOASC Precision Oncology Symposium 2026